<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1709">
  <stage>Registered</stage>
  <submitdate>10/10/2007</submitdate>
  <approvaldate>10/10/2007</approvaldate>
  <nctid>NCT00542919</nctid>
  <trial_identification>
    <studytitle>A Study for Patients With Non-Hodgkin's Lymphomas</studytitle>
    <scientifictitle>A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>H6Q-MC-S057</secondaryid>
    <secondaryid>11503</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>T-Cell Lymphoma</healthcondition>
    <healthcondition>B-Cell Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - enzastaurin

Experimental: 1 - Indolent B-Cell

Experimental: 2 - Aggressive B-Cell

Experimental: 3 - T-Cell


Treatment: drugs: enzastaurin
1125 mg loading dose then 500 mg, oral, daily until progressive disease

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tumor response rate</outcome>
      <timepoint>baseline to measured progressive disease</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>baseline to measured progressive disease</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progressive disease</outcome>
      <timepoint>baseline to measured progressive disease</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>time of response to progressive disease</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>1 Year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>every cycle</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Have measurable lesions

          -  Have recovered from prior chemotherapies

          -  Have an estimated life expectancy of at least 12 weeks

          -  Hepatic: total bilirubin less than or equal to 1.5 XULN; ATL/AST less than or equal to
             2.0 x ULN (less than 5x if liver metastases are present)

          -  Renal: serum creatinine less than or equal to 1.5XULN

          -  Adequate bone marrow reserve: platelets greater than or equal to 75 x 109 /L, absolute
             neutrophil count (ANC) greater than or equal to 1.0 x 09 /L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have a second primary malignancy (except adequately treated nonmelanomatous skin
             cancer, or other cancer that is considered cured by surgical resection or radiation).

          -  Anti-lymphoma therapy within the past 3 weeks

          -  Unable to swallow tablets

          -  Unable to discontinue use of carbamazepine, phenobarbital and phenytoin at least 14
             days prior to study enrollment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>64</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,VIC</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Garran</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Gosford</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Auchenflower</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Prahran</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2250 - Gosford</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Brasilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Jau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SÃ£o Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Chennai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Kolkata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Navrangpura</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Secunderabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Trivandrum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Tepic</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Tlalpan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>In this study, all patients will get investigational drug. There will be no comparator drug.
      This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and
      Aggressive B-cell lymphoma. Each tumor type will include several tumor subtypes:

        -  T-cell lymphoma: Peripheral and Cutaneous T-cell lymphoma (PTCL, CTCL)

        -  Indolent B-cell lymphoma: Small lymphocytic lymphoma, follicular lymphoma (Gr 1 or 2)
           and marginal zone lymphoma

        -  Aggressive B-cell lymphoma: Primary CNS lymphoma, follicular lymphoma (Gr 3a and 3b) and
           aggressive lymphoma with prior clinical history of indolent lymphoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00542919</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>